E
Elpis Biopharmaceuticals
Developing oncology protein degrading therapeutics
About Elpis Biopharmaceuticals
Elpis Biopharmaceuticals operates in the biopharmaceutical sector, focusing on the development of advanced cancer therapies. The company leverages its proprietary mSCAFoldTM technology to engineer cytokines and chemokines that stimulate immune cells, such as NK cells and cytotoxic T cells, to target and eradicate tumor lesions. Additionally, Elpis is developing bispecific antibodies designed to recognize multiple tumor surface antigens and activate immune cells, addressing the complex pathogenesis of cancer driven by various signaling pathways and genetic alterations. The company primarily serves the oncology market, aiming to provide effective therapeutic solutions for cancer patients. Elpis Biopharmaceuticals generates revenue through the development and potential commercialization of its proprietary cancer therapies. Key clients include healthcare providers and institutions involved in cancer treatment.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2020 | $30M | $120M | Undisclosed | — |
| DEBT✓Debt | May 2020 | $150K | — | U.S. Small Business Administration | — |
Growth signals
Latest recorded traffic for Elpis Biopharmaceuticals is 2.2K monthly website visits, up 400% over the last three months. Elpis Biopharmaceuticals's team declined 8.3% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Elpis Biopharmaceuticals in the Lexington ecosystem
The Elpis Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
U.S. Small Business Administration
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Elpis Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Elpis Biopharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.